Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, and VICP Program;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
CMMI Medicaid Proposed Rebate Rule.
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Issues related to pharmaceutical IP and supply chain.
Issues related to appropriations and federal health programs; reimbursement issues; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47.
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Duration: January 1, 2014
to
present
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Budget/Appropriations , Copyright/Patent/Trademark , Homeland Security , Animals
Spending: about $1,440,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Agriculture - Dept of (USDA), Agriculture - Dept of (USDA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
John Green Dep Chief of Staff/Leg Aide, Senator Trent Lott
Stewart Hall Legislative Director, Senator Richard Shelby
Todd M. Weiss SrPolAdv,Hutchinson;LA/LD,Santorum;Staff,HouseIntlRelComm
Hunter Moorhead Adv,Cochran;NatlEcoCoun;SenAppro;LACochran;HRAg;LAParker
Matt Wise LegDirector/LegAide, Rep.Mary Fallin; LC, Sen.Conrad Burns
Steve Tilton HCRPolCoor/SenPolAdvr:ENG/CommBilirakis
Anne W. Brady Deputy Chief of Staff, Rep. Mark Schauer
Jake Perry Legislative Aide, Sen. Harry Reid
Elizabeth Hart CoS,Cong. John Carney;CoS/Dep CoS/LD,Cong. Melissa Bean;Sr. LA,Cong. Baron Hill
Jason Van Pelt Legislative Director, Senior LA, LA, Staff Asst: Cong. Ed Whitfield
Shay Hancock MLA Sen. Murray (D-WA), LA Rep Smith (D-WA)
Katherine Dapper Staff Asst. Sen. Murray (D-WA)
Salim Alameddin Legislative Asst/Legislative Aide, Rep. Will Hurd; Legislative Correspondent/Staff Asst, Sen. John Cornyn
Jason Gleason Chief of Staff/Legislative Director, Rep. John Sarbanes; Legislative Director/Legislative Asst/Legislative Correspondent/Staff Asst, Sen. Paul Sarbanes
Brittany Hernandez Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen
Thomas J. Lucas Legislative Assistant, Legislative Aide, Legislative Correspondent, Staff Assistant: Senator Joe Manchin III
Cheryl Jaeger Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
Mathew Lapinski n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on April 22.
Original Filing: 301572381.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, and VICP Program;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
CMMI Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement issues; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2023
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Jan. 22.
Original Filing: 301536570.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, VICP Program, and insulin price cap;
Animal Drug User Fee Reauthorization, H.R.5860, Making continuing appropriations for fiscal year 2024, and for other purposes;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement issues; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2023
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301513440.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, VICP Program, and insulin price cap;
Animal Drug User Fee Reauthorization, H.R.5860, Making continuing appropriations for fiscal year 2024, and for other purposes;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023; H.R.5378, Lower Costs, More Transparency Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement issues; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2023
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301489823.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, VICP Program, and insulin price cap;
Animal Drug User Fee Reauthorization;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement issues; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2023
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301463242.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, VICP Program, and insulin price cap;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
H.R.830, HELP Copays Act;
S.127, Pharmacy Benefit Manager Transparency Act of 2023;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
Animal Drug User Fee Reauthorization.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Issues related to R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement issues; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2022
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301437289.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, VICP Program, and PDUFA Reauthorization; Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) implementation; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; S.2428, False Claims Amendments Act of 2021; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Issues related to R&D tax credit; FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement and vial size issues; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2022
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Oct. 19, 2022.
Original Filing: 301412175.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, antimicrobial resistance legislation, and PDUFA Reauthorization.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement and vial size issues; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2022
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301392050.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, antimicrobial resistance legislation, and PDUFA Reauthorization.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement and vial size issues; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2022
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on April 20, 2022.
Original Filing: 301366058.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, antimicrobial resistance legislation, and PDUFA Reauthorization.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement and vial size issues; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2021
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Jan. 19, 2022.
Original Filing: 301329885.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and antimicrobial resistance legislation.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement and vial size issues;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502/S.3062); FY2022 Consolidated Appropriations Act (H.R.4502);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2021
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Oct. 19, 2021.
Original Filing: 301305407.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and antimicrobial resistance legislation.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement and vial size issues;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502); FY2022 Consolidated Appropriations Act (H.R.4502);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2021
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on July 19, 2021.
Original Filing: 301283684.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and antimicrobial resistance legislation.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement and vial size issues;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2021
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on April 20, 2021.
Original Filing: 301265263.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and antimicrobial resistance legislation.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Executive Order on Access to Affordable Life-saving Medications (E.O.13937); Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O.13938); Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O.13939); Executive Orders on Lowering Drug Prices by Putting America First (E.O.13947, E.O.13948); Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O.13944); Executive Order on An America-First Healthcare Plan (E.O.13951).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to appropriations and federal health programs; reimbursement and vial size issues;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2020
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240216.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and COVID-19 liability protection legislative proposals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1712/H.R.4100, DISARM Act of 2019.
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021.
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019; S.2543, Prescription Drug Pricing Reduction Act of 2019; H.R.19, Lower Costs, More Cures Act of 2019; S.1895, Lower Health Care Costs Act of 2019; H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to supplemental appropriations and federal health programs;
FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610), FY2021 Consolidated Appropriations Act (H.R.7608);
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617), Reimbursement and vial size issues;
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; The HEALS Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act; H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2020
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Oct. 20, 2020.
Original Filing: 301217705.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and COVID-19 liability protection legislative proposals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1712/H.R.4100, DISARM Act of 2019.
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021.
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
S.1895, Lower Health Care Costs Act of 2019.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to supplemental appropriations and federal health programs;
FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610), FY2021 Consolidated Appropriations Act (H.R.7608);
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617), Reimbursement and vial size issues;
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; The HEALS Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2020
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on July 20, 2020.
Original Filing: 301196733.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and education around COVID-19 therapies.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
S.1712/H.R.4100, DISARM Act of 2019.
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021.
H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020.
H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.6201, Families First Coronavirus Response Act (P.L.116-127).
H.R.748, CARES Act (P.L.116-136) implementation.
H.R.6800, The Heroes Act.
H.R.1425, State Health Care Premium Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
FY 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations;
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123);
Reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2020
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on April 18, 2020.
Original Filing: 301172025.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, importation of biopharmaceuticals, and the international pharmaceutical supply chain.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.6201, Families First Coronavirus Response Act (P.L.116-127).
H.R.748, CARES Act (P.L.116-136).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
FY 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations;
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123);
Reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2019
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Jan. 20, 2020.
Original Filing: 301122245.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Vaccine provisions and TRICARE Pilot Program in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020 (P.L.116-92).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure;
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure;
H.R.1865, Further Consolidated Appropriations Act, 2020 (P.L.116-94);
Reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Oct. 19, 2019.
Original Filing: 301071958.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Vaccine provisions and TRICARE Pilot Program in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020.
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure.
Reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on July 19, 2019.
Original Filing: 301052916.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, and the importation of biopharmaceuticals.
H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Vaccine provisions and TRICARE Pilot Program in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020.
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure.
Reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on April 21, 2019.
Original Filing: 301032838.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), drug pricing, and the 340B Program.
H.R.269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019.
Vaccine provisions and TRICARE Pilot Program in the National Defense Authorization Act for Fiscal Year 2020.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6);
FY 2020 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
FY 2020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations;
Reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Jan. 22, 2019.
Original Filing: 301014294.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), the 340B Program, animal health, drug pricing, oncology coverage, and direct-to-consumer (DTC) advertising;
Vaccine provisions and TRICARE Pilot Program in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019 (P.L.115-232);
Implementation of P.L.114-255, 21st Century Cures Act;
S.2434/H.R.5554, Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (P.L.115-234);
S.2852/H.R.6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
H.R.6, SUPPORT for Patients and Communities Act (P.L.115-271);
H.R.2/S.3042, Agriculture Improvement Act of 2018 (P.L.115-334);
H.R.6642, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
H.R.88, Retirement, Savings, and Other Tax Relief Act of 2018 and Taxpayer First Act of 2018.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245);
TRICARE formulary, reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990841.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), the 340B Program, animal health, drug pricing, oncology coverage, and direct-to-consumer (DTC) advertising;
Vaccine provisions and TRICARE Pilot Program in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019 (P.L.115-232);
Implementation of P.L.114-255, 21st Century Cures Act;
Implementation of P.L.115-176, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017;
S.2434/H.R.5554, Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (P.L.115-234);
S.2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
H.R.6378, To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act;
H.R.6, SUPPORT for Patients and Communities Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Part D Medicare Program (including Coverage Gap and other offsets).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
S.3158/H.R.6470, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019;
H.R.6157/S.3159, Department of Defense Appropriations Act, 2019;
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245);
TRICARE formulary, reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on July 19, 2018.
Original Filing: 300972528.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), the 340B Program, animal health, drug pricing, and oncology coverage;
Vaccine provisions and TRICARE Pilot Program in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019;
Implementation of P.L.114-255, 21st Century Cures Act;
H.R.878, Trickett Wendler Right to Try Act of 2017/S.204, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (P.L.115-176);
S.2434, Animal Drug and Animal Generic Drug User Fee Amendments of 2018;
S.2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Part D Medicare Program (including Coverage Gap and other offsets).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
S.3158/House Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019;
H.R.6157/S.3159, Department of Defense Appropriations Act, 2019;
TRICARE formulary, reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $40,000. The report was filed on April 20, 2018.
Original Filing: 300953792.xml
Lobbying Issues
Vaccine provisions and TRICARE Pilot Program in the FY19 National Defense Authorization Act.
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
S.2434, Animal Drug and Animal Generic Drug User Fee Amendments of 2018.
P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA).
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health and oncology coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; H.R.3219/Senate, Department of Defense Appropriations Act, 2018; H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96); H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123); H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141); TRICARE formulary, reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on Jan. 20, 2018.
Original Filing: 300931676.xml
Lobbying Issues
H.R.2810, National Defense Authorization Act for Fiscal Year 2018 (P.L.115-91), vaccine provisions and TRICARE Pilot Program.
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health and oncology coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1, Tax Cuts and Jobs Act (P.L.115-97); issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; H.R.3219/Senate, Department of Defense Appropriations Act, 2018; H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes (P.L.115-90); H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes; H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96); TRICARE formulary, reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on Oct. 19, 2017.
Original Filing: 300907883.xml
Lobbying Issues
H.R.2810/Senate, National Defense Authorization Act for Fiscal Year 2018, vaccine provisions and TRICARE Pilot Program.
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
H.R.2430/S.934, FDA Reauthorization Act of 2017(P.L.115-52).
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health and oncology coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; H.R.3219, Department of Defense Appropriations Act, 2018; H.R.3354, Make America Secure and Prosperous Appropriations Act, 2018; TRICARE formulary, reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300891716.xml
Lobbying Issues
H.R.2810/Senate, National Defense Authorization Act for Fiscal Year 2018, vaccine provisions and TRICARE Pilot Program.
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
H.R.2430/S.934, FDA Reauthorization Act of 2017.
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health and oncology coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2018, Department of Defense Appropriations; H.R.244, Consolidated Appropriations Act 2017 (P.L.115-31); TRICARE formulary, reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on April 19, 2017.
Original Filing: 300869054.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act. S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health and oncology coverage. P.L.114-328, National Defense Authorization Act for Fiscal Year 2017, vaccine provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; S.Con.Res.3, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026; Tricare formulary, reimbursement and vial size issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847947.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144). H.R.512, DISARM Act of 2015. H.R.34, 21st Century Cures Act (P.L.114-255). S.2912, Trickett Wendler Right to Try Act 2016. Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health and oncology coverage. P.L.114-328, National Defense Authorization Act for Fiscal Year 2017, vaccine provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform. Issues related to Treasury regulations on Section 385.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Trans-Pacific Partnership (TPP).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; S.3040/H.R.5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017; reimbursement issues; vial size issues. H.R.5293/S.3000, Department of Defense Appropriations Act, 2017; Tricare formulary issues. H.R.2028, Further Continuing and Security Assistance Appropriations Act, 2017 (P.L.114-254).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on Oct. 18, 2016.
Original Filing: 300831064.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144). H.R.512, DISARM Act of 2015. H.R.6, 21st Century Cures Act. S.2912, Trickett Wendler Right to Try Act 2016. Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health, Senate HELP Innovation Project and oncology coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform. Issues related to Treasury regulations on Section 385.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Trans-Pacific Partnership (TPP).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; S.3040/H.R.5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017; reimbursement issues; vial size issues. H.R.5293/S.3000, Department of Defense Appropriations Act, 2017; Tricare formulary issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to cybersecurity and data breach legislation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on July 19, 2016.
Original Filing: 300815701.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144). H.R.512, DISARM Act of 2015. H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health, Senate HELP Innovation Project and oncology coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform. Issues related to Treasury regulations on Section 385.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Trans-Pacific Partnership (TPP).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; S.3040/House Committee Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017; reimbursement issues; vial size issues. H.R.5293/S.3000, Department of Defense Appropriations Act, 2017; Tricare formulary issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on April 19, 2016.
Original Filing: 300795149.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.512, DISARM Act of 2015. H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health, Senate HELP Innovation Project and oncology coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. Issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Trans-Pacific Partnership (TPP).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.Con.Res.125, Establishing the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026. FY2017 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations. FY2017 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. Reimbursement issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on Jan. 19, 2016.
Original Filing: 300775221.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.512, DISARM Act of 2015. H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health, Senate HELP Innovation Project and oncology coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
general issues related to Medicare and Medicaid
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.1946, Tax Relief Extension Act of 2015; P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to tax extenders and corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to agricultural trade, Trans-Pacific Partnership (TPP) negotiations and Trade Promotion Authority (TPA). P.L.114-27, Trade Preferences Extension Act of 2015, H.R.1314, Trade Act of 2015 and P.L.114-26, Defending Public Safety Employees' Retirement Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3049/S.1800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; P.L.114-74, Bipartisan Budget Act of 2015; P.L.114-113, Consolidated Appropriations Act, 2016; various issues including health, tax and cybersecurity.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.234, Cyber Intelligence Sharing and Protection Act, S.456, Cyber Threat Sharing Act of 2015, S.754, Cybersecurity Information Sharing Act of 2015, S.961/H.R.2205, Data Security Act of 2015, S.1158, Consumer Privacy Protection Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, H.R.1704, Personal Data Notification and Protection Act of 2015, H.R.1560, Protecting Cyber Networks Act, H.R.1731, National Cybersecurity Protection Advancement Act; cybersecurity issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on Oct. 16, 2015.
Original Filing: 300755668.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.512, DISARM Act of 2015. H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), 340B Program, animal health and Senate HELP Innovation Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
general issues related to Medicare and Medicaid
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.1946, Tax Relief Extension Act of 2015.
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to agricultural trade, Trans-Pacific Partnership (TPP) negotiations and Trade Promotion Authority (TPA). P.L.114-27, Trade Preferences Extension Act of 2015, H.R.1314, Trade Act of 2015 and P.L.114-26, Defending Public Safety Employees' Retirement Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3049/S.1800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations. H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.234, Cyber Intelligence Sharing and Protection Act, S.456, Cyber Threat Sharing Act of 2015, S.754, Cybersecurity Information Sharing Act of 2015, S.961/H.R.2205, Data Security Act of 2015, S.1158, Consumer Privacy Protection Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, H.R.1704, Personal Data Notification and Protection Act of 2015, H.R.1560, Protecting Cyber Networks Act, H.R.1731, National Cybersecurity Protection Advancement Act; cybersecurity issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on July 17, 2015.
Original Filing: 300739661.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.512, DISARM Act of 2015. H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), the 340B Program and animal health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
general issues related to Medicare and Medicaid
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to agricultural trade, Trans-Pacific Partnership (TPP) negotiations and Trade Promotion Authority (TPA). P.L.114-27, Trade Preferences Extension Act of 2015, H.R.1314, Trade Act of 2015 and P.L.114-26, Defending Public Safety Employees' Retirement Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
FY2016 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations. H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.234, Cyber Intelligence Sharing and Protection Act, S.456, Cyber Threat Sharing Act of 2015, S.754, Cybersecurity Information Sharing Act of 2015, S.961/H.R.2205, Data Security Act of 2015, S.1158, Consumer Privacy Protection Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, H.R.1704, Personal Data Notification and Protection Act of 2015, H.R.1560, Protecting Cyber Networks Act, H.R.1731, National Cybersecurity Protection Advancement Act; cybersecurity issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $30,000. The report was filed on April 17, 2015.
Original Filing: 300719485.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.512, DISARM Act of 2015. Issues related to health care, the Food and Drug Administration (FDA), 21st Century Cures, the 340B Program and animal health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
general issues related to Medicare and Medicaid
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to agricultural trade.
Issues associated with Trans-Pacific Partnership (TPP) negotiations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
FY2016 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations. H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $20,000. The report was filed on Jan. 16, 2015.
Original Filing: 300697531.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.4187, DISARM Act of 2014. Issues related to health care and the Food and Drug Administration (FDA). Issues related to the 340B Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
general issues related to Medicare and Medicaid
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.2260, EXPIRE Act of 2014; issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to agricultural trade.
Issues associated with Trans-Pacific Partnership (TPP) negotiations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to animal drugs and animal health.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $20,000. The report was filed on Oct. 16, 2014.
Original Filing: 300678639.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.4187, DISARM Act of 2014. Issues related to health care and the Food and Drug Administration (FDA). Issues related to the 340B Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
general issues related to Medicare and Medicaid
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.2260, EXPIRE Act of 2014, issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to agricultural trade.
Issues associated with Trans-Pacific Partnership (TPP) negotiations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to animal drugs and animal health.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $20,000. The report was filed on July 18, 2014.
Original Filing: 300661533.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.4187, DISARM Act of 2014. Issues related to health care and the Food and Drug Administration (FDA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
general issues related to Medicare and Medicaid
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.2260, EXPIRE Act of 2014, issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to agricultural trade.
Issues associated with Trans-Pacific Partnership (TPP) negotiations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to animal drugs and animal health.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, Crossroads Strategies, LLC lobbied for Merck & Co., Inc. , earning $20,000. The report was filed on April 17, 2014.
Original Filing: 300638838.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144).
Issues related to health care and the Food and Drug Administration (FDA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4302, Protecting Access to Medicare Act of 2014; general issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to agricultural trade.
Issues associated with Trans-Pacific Partnership (TPP) negotiations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to animal drugs and animal health.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
Crossroads Strategies, LLC filed a lobbying registration on Feb. 11, 2014 to represent Merck & Co., Inc., effective Jan. 1, 2014.
Original Filing: 300630373.xml
Issue(s) they said they’d lobby about: Issues related to the implementation of the Patient Protection and Affordable Care Act, FDASIA implementation, health care, the FDA, Medicare and Medicaid, taxes, trade and animals. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...